ArticleJournal of cellular physiology2019
Prognostic scoring system for osteosarcoma using network-regularized high-dimensional Cox-regression analysis and potential therapeutic targets.
Article in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A Retrospective Study of a Postoperative Inflammation-Based Score for Predicting Disease-Free Survival in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy.Cancer management and research · 2026Article
- Establishment of a mInternational journal of genomics · 2026Article
- Development of a Machine Learning-Powered Optimized Lung Allocation System for Maximum Benefits in Lung Transplantation: A Korean National Data.Journal of Korean medical science · 2025Article
- Review
- Corrigendum.Journal of cellular physiology · 2023Article
- Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer with neoadjuvant chemoradiotherapy.World journal of gastrointestinal oncology · 2022Article
- Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma.BMC medical genomics · 2022Article
- Expression of immune-related genes as prognostic biomarkers for the assessment of osteosarcoma clinical outcomes.Scientific reports · 2021Article
- Identification of a 3-gene signature based on differentially expressed invasion genes related to cancer molecular subtypes to predict the prognosis of osteosarcoma patients.Bioengineered · 2021Article
- Prognostic nomogram for predicting 5-year overall survival in Chinese patients with high-grade osteosarcoma.Scientific reports · 2021Article
- Identification and Complete Validation of Prognostic Gene Signatures for Human Papillomavirus-Associated Cancers: Integrated Approach Covering Different Anatomical Locations.Journal of virology · 2021Article
- Article
- A User-Friendly, Web-Based Integrative Tool (ESurv) for Survival Analysis: Development and Validation Study.Journal of medical Internet research · 2020Article
- Identification and Development of a Novel 4-Gene Immune-Related Signature to Predict Osteosarcoma Prognosis.Frontiers in molecular biosciences · 2020Article
- Prognostic Significance of COVID-19 Receptor ACE2 and Recommendation for Antihypertensive Drug in Renal Cell Carcinoma.BioMed research international · 2020Article
- Co-expression network analysis identifies a gene signature as a predictive biomarker for energy metabolism in osteosarcoma.Cancer cell international · 2020Article
- Article
- Prognostic scoring system for osteosarcoma using network-regularized high-dimensional Cox-regression analysis and potential therapeutic targets.Journal of cellular physiology · 2019Article
- Evaluation of the prognostic significances of γ-secretase genes in pancreatic cancer.Oncology letters · 2019Article
- VNN3 is a potential novel biomarker for predicting prognosis in clear cell renal cell carcinoma.Animal cells and systems · 2019Article
Corrections and comments
- Erratum issuedCorrigendum.2023
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the recent emphasis on the importance of personalized genomic medicine, studies have performed prognostic stratification using gene signatures in cancers. However, these studies have not considered gene networks with clinical data. Therefore, this study aimed to develop a novel prognostic score using grouped variable selection for patients with osteosarcoma. We assessed messenger RNA (mRNA) expression and clinical data from Gene Expression Omnibus to develop a novel prognostic scoring system for patients with osteosarcoma. Variable selection using Network-Regularized high-dimensional Cox-regression analysis with information regarding gene networks obtained from six large pathway databases was performed. We determined the risk score on the linear combination of regression coefficients and mRNA expression values. Log-rank test, UNO's c-index, and area under the curve (AUC) values were determined to evaluate the discriminatory power between the low- and high-risk groups. A recently reported next-generation Connectivity Map was used to identify future therapeutic targets for osteosarcoma. Our novel model had significantly high discriminatory power in predicting overall survival. An optimal c-index of 0.967 was obtained and time-dependent receiver operating characteristic analysis revealed an acceptable predictive value of AUC between 0.953 and 1.000. Knockdown of BACE2 or ING2 and linifanib treatment may improve the prognosis of patients with osteosarcoma. Herein, this novel prognostic scoring system would not only facilitate a more accurate prediction of patient prognosis, but also contribute to the selection of suitable therapeutic alternatives for osteosarcoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.